Study role testosterone may play in triple negative breast cancer

March 23, 2012

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

Lead researcher Barbara Pockaj, M.D., a at Mayo Clinic in Arizona will present the results of the study at the 65th annual Society of Surgical Oncology conference on March 23 in Orlando, Fla.

TNBC is highly aggressive and affects approximately 10 to 20 percent of . The disease is characterized by larger, faster-growing tumors than other types of breast cancer and has limited treatment options.

Unlike other forms of in which treatments are tailored to specifically target such as estrogen and progesterone or the HER-2 proteins that promote the growth and spread of , triple negative cancer cells do not possess markers for estrogen, progesterone or HER-2, Dr. Pockaj says. There are no targeted therapies other than chemotherapy to TNBC, she says.

Researchers at Mayo Clinic and say that could change if the androgen (testosterone) receptor shows potential as a .

"The goal of the study was to define what may be fueling TNBC, thereby identifying new potential options for effective targeted treatment," says co-lead researcher Heather Cunliffe, Ph.D., Associate Professor and head of TGen's breast and ovarian cancer research unit. "The team discovered that the androgen receptor is expressed in a significant proportion of these tumors, and moreover, the androgen-receptive positive tumors shared a unique clinical behavior."

Researchers found 22 percent of the patients with TNBC had the androgen receptor in their tumors.

"These cancers appeared in women who were older and there was a higher likelihood of the cancer spreading to the lymph nodes. Even though the women with androgen-receptor positive TNBC had more aggressive cancer to start, their survival was no different than patients with TNBC whose cancers did not possess the androgen receptor," Dr. Pockaj says. "Importantly, while all normal breast tissue had androgen receptors, it was lost in the majority of patients with TNBC. Our data shows us that there is a definitive group of patients who may be sensitive to treatment directed against the androgen receptor."

While further research with a larger number of patients is needed to define clinical implications of androgen receptor positive TNBC, Dr. Cunliffe says this study provides important insights.

An important next step of the research will be to determine how the functions in TNBC.

"We will look at all the genes within the cancer cells from each patient using genomic approaches. This way we can find ways to manipulate the cancer cell which hopefully will translate into new treatment strategies for the women with TNBC," Dr. Pockaj says.

Explore further: Different subtypes of triple-negative breast cancer respond to different therapies

Related Stories

Different subtypes of triple-negative breast cancer respond to different therapies

June 27, 2011
Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)."

Study finds new points of attack on breast cancers not fueled by estrogen

July 11, 2011
Although it sounds like a case of gender confusion on a molecular scale, the male hormone androgen spurs the growth of some breast tumors in women. In a new study, scientists at Dana-Farber Cancer Institute provide the first ...

Study identifies new prostate cancer drug target

February 6, 2012
Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.